Company Overview and News

14
Xylem Can Satisfy The World's Thirst For Water

2018-10-09 seekingalpha
Digitizing the water business is just beginning, and Xylem is well-positioned to take advantage of this multi-decade trend.
BGX PUR XYL BX BGLF BGB

 
Xylem's Strategy Has A Flaw

2018-08-24 seekingalpha
M&A has been a major part of the company's strategy, but the balance sheet appears stretched.
PUR XYL

 
DIRTT Environmental Solutions Ltd (DRTTF) Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
DIRTT Environmental Solutions Ltd (OTCPK:DRTTF) Q2 2018 Earnings Conference Call August 9, 2018 10:00 AM ET
PUR DRTTF XYL

 
Xylem (XYL) Battles Cost Pressure on Solid Growth Drivers

2018-07-09 zacks
On Jul 9, we issued an updated research report on premium diversified machinery company, Xylem Inc. (XYL - Free Report) . The company currently carries a Zacks Rank #3 (Hold). Over the past 60 days, the Zacks Consensus Estimate for the stock’s earnings remained unchanged for both 2018 and 2019 at $2.89 and $3.37, respectively, reflecting neutral brokers’ sentiments. Let’s dig into the fundamental aspects influencing the performance of this stock.
ROP POOL GGG PUR XYL GTLS

 
DIRTT Announces New Chief Financial Officer

2018-05-28 globenewswire
CALGARY, Alberta, May 28, 2018 (GLOBE NEWSWIRE) -- DIRTT Environmental Solutions Ltd. (“DIRTT” or the “Company”) (TSX:DRT), an interior construction company using technology for client-driven design and manufacturing, today announced the appointment of Geoffrey D. Krause, CA, CPA, as its chief financial officer, effective June 4, 2018.
PUR DRTTF XYL DRT

 
Xylem (XYL) Q1 2018 Results - Earnings Call Transcript

2018-05-01 seekingalpha
Welcome to the Xylem First Quarter 2018 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode and the floor will be open for your questions following the presentation.
PUR XYL

56
Xylem (XYL) to Report Q1 Earnings: What's in the Cards?

2018-04-27 zacks
Xylem Inc. (XYL - Free Report) is slated to report first-quarter 2018 results before the opening bell on May 1. In the last four quarters, the company reported better-than-expected results in two quarters, while lagged estimates in one and met in the other. The average four-quarter earnings surprise is a negative 0.02%. In the last reported quarter, its earnings of 76 cents came in line with the Zacks Consensus Estimate.
CATR PUR CAT XYL SAH ALRM

4
DIRTT and Iron Compass agree on board refreshment

2018-04-16 globenewswire - 1
CALGARY, Alberta, April 16, 2018 (GLOBE NEWSWIRE) -- DIRTT Environmental Solutions Ltd. (“DIRTT” or the “Company”) (TSX:DRT), an interior construction company using technology for client-driven design and manufacturing, announces it has agreed with recommendations provided by Iron Compass, LLC to add John (Jack) Elliott and Ronald Kaplan to the board of directors of the Company (the “Board”), effective immediately.
HSC PUR TREX DRTTF DRT

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:PUR / Pure Technologies Ltd on message board site Silicon Investor.

Coherus BioSciences: Pure Play In The Emerging Biosimilar In Coherus BioSciences: Pure Play In The Emerging Biosimilar In Coherus BioSciences: Pure Play In The Emerging Biosimilar In CFA Vs. Columbia Business School Vs. Pure Self-education CFA Vs. Columbia Business School Vs. Pure Self-education CFA Vs. Columbia Business School Vs. Pure Self-education
CFA Vs. Columbia Business School Vs. Pure Self-education CFA Vs. Columbia Business School Vs. Pure Self-education CFA Vs. Columbia Business School Vs. Pure Self-education Intu0027l Pursuit (T.IPJ) Intu0027l Pursuit (T.IPJ) Intu0027l Pursuit (T.IPJ)
HAWKEYE GOLD PURCHASE TOP PROPERTY - YUKON HAWKEYE GOLD PURCHASE TOP PROPERTY - YUKON HAWKEYE GOLD PURCHASE TOP PROPERTY - YUKON ADOT - BIOMODA: Profitable Technology with Purpose ADOT - BIOMODA: Profitable Technology with Purpose ADOT - BIOMODA: Profitable Technology with Purpose
Do handguns serve a purpose other than killing people? Do handguns serve a purpose other than killing people? Do handguns serve a purpose other than killing people? SPUR VENTURES STARTING TO MOVE TARGET 9.00 SPUR VENTURES STARTING TO MOVE TARGET 9.00 SPUR VENTURES STARTING TO MOVE TARGET 9.00
Biopure Corp (BPUR) Biopure Corp (BPUR) Biopure Corp (BPUR) Trivial Pursuit Trivial Pursuit Trivial Pursuit